+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Infertility (Testing and Treatment) Market 2019-2027

  • ID: 4774269
  • Report
  • Region: Asia Pacific
  • 124 pages
  • Triton Market Research
UP TO OFF
until Jan 31st 2020
1 of 3

FEATURED COMPANIES

  • Andrology Solutions
  • Esco Micro Pte. Ltd.
  • Genea
  • Irvine Scientific
  • Origio
  • Progyny
  • MORE
Market Outlook

The Asia Pacific infertility (testing and treatment) market is expected to rise at a CAGR of 7.80% throughout the forecast period 2019-2027.

India, China, Japan, South Korea, ASEAN countries, Australia & New Zealand and rest of APAC form the infertility (testing and treatment) market in the Asia-Pacific region. The market in the region is driven by low-surrogacy cost in India, rising disposable incomes and an increase in infertility due to an unhealthy lifestyle. Also, the aging population and low birth rates in countries such as South Korea, Singapore and Japan are expected to drive the market demand.

Japan has the highest proportion of the aging population. In addition, the initiatives taken by governments in their respective regions for substantial investments in the pharmaceutical industry and healthcare are providing opportunities for the market to grow over the forecasting years.

A rising trend of medical tourism has been observed in Asia-Pacific countries. The preferable countries for infertility treatments are India and Thailand. The major reason for the high rate of medical tourism in these countries is the low cost of treatment. In India, the cost of IVF is 70% of the total IVF cost in the US. Moreover, the presence of highly-skilled doctors and developed infrastructure in India is also increasing medical tourism in India. Thailand provides gender selection options and is a popular destination for couples looking for family balance.

The infertility (testing and treatment) market in China is anticipated to grow at a significant pace during the forecast period. China is the second largest market after Japan. A considerable percentage of men and women of reproductive age in China have infertility issues and also have limited access to ART facilities. The fertility rate in China is increasing. However, the government is taking IVF as a method to control birth rates. China, with its one-child policy, has a high number of families that desperately need a single child. The country was offering IVF treatments through government-run hospitals till the mid-nineties. A population close to 1.3 billion is a massive market in itself even if infertility rates are in line with the global infertility rates.

Competitive Outlook

The key companies profiled in the report include Genea, Endo Pharmaceuticals, Andrology Solutions, OvaScience, Vitrolife AB, The Cooper Companies, Inc., Progyny, Esco Micro Pte. Ltd., Halotech DNA, Quest Diagnostic, Ferring Pharmaceuticals, Merck, Irvine Scientific, Origio and Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Andrology Solutions
  • Esco Micro Pte. Ltd.
  • Genea
  • Irvine Scientific
  • Origio
  • Progyny
  • MORE
1. Infertility (Testing And Treatment) Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Key Insights
2.2.1. Ivf Dominates the Female Treatment Market
2.2.2. Oxidative Stress Analysis is the Fastest Growing Male Infertility Testing Market
2.3. Porter’s Five Force Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitute
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Intensity of Competitive Rivalry
2.4. Key Impact Analysis
2.4.1. Treatment Options
2.4.2. Quality of Medical Procedures
2.4.3. Price of Treatments
2.4.4. Shift Towards Medical Tourism
2.4.5. Reimbursement
2.5. Market Attractiveness Index
2.6. Vendor Scorecard
2.7. Industry Components
2.7.1. Raw Material Procurement
2.7.2. Manufacturing
2.7.3. Supply LoGIStics
2.7.4. Distribution Channels
2.7.5. End-Users
2.8. Regulatory Framework
2.9. Market Drivers
2.9.1. Rise in Infertility And Treatment Awareness
2.9.2. Medical Tourism in Fertility Treatments
2.9.3. Surrogacy Laws Are Getting More Defined
2.9.4. Healthcare Advances Have Fine-Tuned Fertility Treatment
2.9.5. Increasing Effectiveness of Treatments
2.9.6. Healthier Donor Eggs
2.9.7. Introduction of New Testing Devices
2.10. Market Restraints
2.10.1. Treatment Procedure Out of Reach For Many Due to High Costs
2.10.2. Country-Wise Regulatory Issues
2.11. Market Opportunities
2.11.1. Reducing the Cost of Treatment to Make It More Accessible
2.11.2. Ivf Attracting Investments From Private Equity Investors
2.11.3. Diy Testing Increasing Access And Reducing Cost
2.12. Market Challenges
2.12.1. Infertility Considered a Social Taboo Amongst Men
2.12.2. Perils of Multiple Pregnancies
2.12.3. Traditional Treatments Used Widely As An Alternative For Infertility Treatments

3. Infertility (Testing And Treatment) Market Outlook - By Gender
3.1. Male Gender
3.1.1. Testing
3.1.1.1. Dna Fragmentation
3.1.1.2. Oxidative Stress Analysis
3.1.1.3. Sperm Penetration Assay
3.1.1.4. Computer-Assisted Semen Analysis (Casa)
3.1.1.5. Sperm Agglutination
3.1.1.6. Microscopic Examination
3.1.1.7. Others
3.1.2. Treatment
3.1.2.1. Vasovasostomy And Vasoepididymostomy (Vasectomy Reversal)
3.1.2.2. Sperm Retrieval Treatment
3.1.2.3. Microsurgical Sperm Aspiration (Mesa)
3.1.2.4. Testicular Sperm Extraction (Tese)
3.1.2.5. Varicocele Repairs
3.1.2.6. Assisted Reproductive Techniques (Art)
3.1.2.7. Intrauterine Insemination (Iui)
3.1.2.8. In-Vitro Fertilization (Ivf)
3.1.2.9. Intracytoplasmic Sperm Injection (Icsi)
3.2. Female Gender
3.2.1. Female Infertility Testing
3.2.1.1. Ovulation Testing
3.2.1.2. Hysterosalpingography
3.2.1.3. Laparoscopy
3.2.1.4. Transvaginal Ultrasound
3.2.1.5. Ovarian Reserve Testing
3.2.1.6. Hormonal Level Testing
3.2.1.7. Others
3.2.2. Treatment
3.2.2.1. In-Vitro Fertilization
3.2.2.2. Intrauterine Insemination (Iui)
3.2.2.3. Drug And Hormone Therapies

4. Infertility (Testing And Treatment) Market Outlook - By End-Use
4.1. Fertility Clinics
4.2. Hospitals
4.3. Surgical Centers
4.4. Clinical Research Institutes

5. Infertility (Testing And Treatment) Market - Regional Outlook
5.1. Asia-Pacific
5.1.1. Country Analysis
5.1.1.1. China
5.1.1.2. Japan
5.1.1.3. India
5.1.1.4. South Korea
5.1.1.5. Asean Countries
5.1.1.6. Australia & New Zealand
5.1.1.7. Rest of Asia-Pacific

6. Competitive Landscape
6.1. Andrology Solutions
6.2. Endo Pharmaceuticals
6.3. Progyny
6.4. Ferring Pharmaceuticals
6.5. Genea
6.6. Halotech Dna
6.7. Irvine Scientific
6.8. Merck
6.9. Origio
6.10. Ovascience
6.11. Vitrolife Ab
6.12. Thermo Fisher Scientific, Inc.
6.13. the Cooper Companies, Inc.
6.14. Quest Diagnostic
6.15. Esco Micro Pte. Ltd.

7. Research Methodology & Scope
7.1. Research Scope & Deliverables
7.1.1. Objectives of Study
7.2. Sources of Data
7.2.1. Primary Data Sources
7.2.2. Secondary Data Sources
7.3. Research Methodology
7.3.1. Evaluation of Proposed Market
7.3.2. Identification of Data Sources
7.3.3. Assessment of Market Determinants
7.3.4. Data Collection
7.3.5. Data Validation & Analysis

List of Tables
Table 1: Asia-Pacific Infertility (Testing And Treatment) Market, By Country, 2019-2027 (In $ Million)
Table 2: Market Attractiveness Index
Table 3: Vendor Scorecard
Table 4: Regulatory Framework
Table 5: Average Cost Comparison of Infertility Treatments
Table 6: Asia-Pacific Infertility (Testing And Treatment) Market, By Country, 2019-2027 (In $ Million)
Table 7: Growth in Ivf Clinics in Asia
Table 8: Asia-Pacific Infertility (Testing And Treatment) Market, By Gender, 2019-2027 (In $ Million)
Table 9: Asia-Pacific Infertility (Testing And Treatment) Market, By Male Gender, 2019-2027 (In $ Million)
Table 10: Asia-Pacific Infertility (Testing And Treatment) Market, By Male Infertility Testing, 2019-2027 (In $ Million)
Table 11: Asia-Pacific Infertility (Testing And Treatment) Market, By Female Gender, 2019-2027 (In $ Million)
Table 12: Asia-Pacific Infertility (Testing And Treatment) Market, By Female Infertility Testing, 2019-2027 (In $ Million)
Table 13: Asia-Pacific Infertility (Testing And Treatment) Market, By End-Use, 2019-2027 (In $ Million)
Table 14: Medical Tourism in South Korea ($ Million)

List of Figures
Figure 1: Asia-Pacific Infertility (Testing And Treatment) Market, By End-User, 2018 & 2027 (In %)
Figure 2: Porter’s Five Force Analysis
Figure 3: Key Buying Impact Analysis
Figure 4: Industry Components
Figure 5: Major Fertility Treatment Destination Ranking
Figure 6: Clinical Algorithm For the Evaluation of Infertile Woman
Figure 7: Rate of Multiple Deliveries
Figure 8: Asia-Pacific Infertility (Testing And Treatment) Market, By Male Gender, 2019-2027 (In $ Million)
Figure 9: Asia-Pacific Infertility (Testing And Treatment) Market, By Testing, 2019-2027 (In $ Million)
Figure 10: Asia-Pacific Infertility (Testing And Treatment) Market, By Dna Fragmentation, 2019-2027 (In $ Million)
Figure 11: Causes of Sperm Dna Fragmentation
Figure 12: Asia-Pacific Infertility (Testing And Treatment) Market, By Oxidative Stress Analysis, 2019-2027 (In $ Million)
Figure 13: Asia-Pacific Infertility (Testing And Treatment) Market, By Sperm Penetration Assay, 2019-2027 (In $ Million)
Figure 14: Asia-Pacific Infertility (Testing And Treatment) Market, By Computer-Assisted Semen Analysis, 2019-2027 (In $ Million)
Figure 15: Asia-Pacific Infertility (Testing And Treatment) Market, By Sperm Agglutination, 2019-2027 (In $ Million)
Figure 16: Asia-Pacific Infertility (Testing And Treatment) Market, By Microscopic Examination, 2019-2027 (In $ Million)
Figure 17: Asia-Pacific Infertility (Testing And Treatment) Market, By Others, 2019-2027 (In $ Million)
Figure 18: Asia-Pacific Infertility (Testing And Treatment) Market, By Treatment, 2019-2027 (In $ Million)
Figure 19: Asia-Pacific Infertility (Testing And Treatment) Market, By Female Gender, 2019-2027 (In $ Million)
Figure 20: Asia-Pacific Infertility (Testing And Treatment) Market, By Female Infertility Testing, 2019-2027 (In $ Million)
Figure 21: Asia-Pacific Infertility (Testing And Treatment) Market, By Ovulation Testing, 2019-2027 (In $ Million)
Figure 22: Asia-Pacific Infertility (Testing And Treatment) Market, By Hysterosalpingography, 2019-2027 (In $ Million)
Figure 23: Asia-Pacific Infertility (Testing And Treatment) Market, By Laparoscopy, 2019-2027 (In $ Million)
Figure 24: Asia-Pacific Infertility (Testing And Treatment) Market, By Transvaginal Ultrasound, 2019-2027 (In $ Million)
Figure 25: Asia-Pacific Infertility (Testing And Treatment) Market, By Ovarian Reserve Testing, 2019-2027 (In $ Million)
Figure 26: Asia-Pacific Infertility (Testing And Treatment) Market, By Hormonal Level Testing, 2019-2027 (In $ Million)
Figure 27: Asia-Pacific Infertility (Testing And Treatment) Market, By Others, 2019-2027 (In $ Million)
Figure 28: Asia-Pacific Infertility (Testing And Treatment) Market, By Female Infertility Treatment, 2019-2027 (In $ Million)
Figure 29: Asia-Pacific Infertility (Testing And Treatment) Market, By Fertility Clinics, 2019-2027 (In $ Million)
Figure 30: Asia-Pacific Infertility (Testing And Treatment) Market, By Hospitals, 2019-2027 (In $ Million)
Figure 31: Asia-Pacific Infertility (Testing And Treatment) Market, By Surgical Centers, 2019-2027 (In $ Million)
Figure 32: Asia-Pacific Infertility (Testing And Treatment) Market, By Clinical Research Institutes, 2019-2027 (In $ Million)
Figure 33: Asia-Pacific Infertility (Testing And Treatment) Market, Regional Outlook, 2018 & 2027 (In %)
Figure 34: China Infertility (Testing And Treatment) Market, 2019-2027 (In $ Million)
Figure 35: Japan Infertility (Testing And Treatment) Market, 2019-2027 (In $ Million)
Figure 36: India Infertility (Testing And Treatment) Market, 2019-2027 (In $ Million)
Figure 37: South Korea Infertility (Testing And Treatment) Market, 2019-2027 (In $ Million)
Figure 38: Asean Countries Infertility (Testing And Treatment) Market, 2019-2027 (In $ Million)
Figure 39: Australia & New Zealand Infertility (Testing And Treatment) Market, 2019-2027 (In $ Million)
Figure 40: Rest of Asia-Pacific Infertility (Testing And Treatment) Market, 2019-2027 (In $ Million)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Andrology Solutions
  • Endo Pharmaceuticals
  • Progyny
  • Ferring Pharmaceuticals
  • Genea
  • Halotech Dna
  • Irvine Scientific
  • Merck
  • Origio
  • Ovascience
  • Vitrolife AB
  • Thermo Fisher Scientific, Inc.
  • The Cooper Companies, Inc.
  • Quest Diagnostic
  • Esco Micro Pte. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll